EVP Stewart Jeffrey Ryan sells 58,832 shares for $12,359,504.28 at ABBV; divests 52.5% of holdings post-transaction.
Stewart Jeffrey Ryan, Chief Commercial Officer of AbbVie, executed two separate sales on 2025-03-31 totaling 58,832 shares at a blended average price of $210.08, reducing his holdings from 112,066 shares to 53,234 shares (a 52.5% reduction). At the time of sale, the stock was trading near its 52-week highs ($216.66), having declined only 5.3% from the peak. Notably, across his cross-ticker track record, Ryan's prior 3 sales achieved a 100.00% well-timed rate at the 90-day mark, with prior sales at ABBV specifically all showing negative 90-day returns (ranging from -5.6% to -5.8%). The current price of $205.19 is already 5.3% below the 52-week high, and the 30-day change of -3.0% suggests early movement consistent with his historical post-sale patterns. This substantial reduction in position size, combined with the insider's established track record of well-timed sells and the stock's proximity to its annual high, warrants investor attention to near-term price momentum.